346
Participants
Start Date
July 31, 2012
Primary Completion Date
October 31, 2014
Study Completion Date
October 31, 2014
Rotigotine
"Transdermal Patch~Content:~4 mg /24 h (20 cm\^2), 6 mg /24 h (30 cm\^2), 8 mg /24 h (40 cm\^2)~For advanced-stage Parkinson's Disease, subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 12 week maintenance period"
Placebo Patch
"Transdermal Patch~Size:~20 cm\^2, 30 cm\^2, 40 cm\^2~Subjects randomized to placebo received matching placebo patches"
L-dopa
Subject must be on a stable dose of L-dopa (either short-acting or sustained release \[in combination with benserazide or carbidopa\]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.
Sp1037 001, Beijing
Sp1037 002, Beijing
Sp1037 019, Beijing
Sp1037 025, Beijing
Sp1037 017, Changchun
Sp1037 007, Chengdu
Sp1037 027, Chengdu
Sp1037 021, Fuzhou
Sp1037 010, Guangzhou
Sp1037 011, Guangzhou
Sp1037 014, Guangzhou
Sp1037 015, Guangzhou
Sp1037 005, Hangzhou
Sp1037 013, Hangzhou
Sp1037 018, Hangzhou
Sp1037 023, Jinan
Sp1037 003, Shanghai
Sp1037 004, Shanghai
Sp1037 009, Shanghai
Sp1037 008, Suzhou
Sp1037 016, Tianjin
Sp1037 006, Wuhan
Sp1037 022, Wuhan
Sp1037 024, Wuhan
Lead Sponsor
UCB Trading (Shanghai) Co. Ltd.
UNKNOWN
UCB Pharma
INDUSTRY